Skip Navigation

Advertise|Press|Contact|FAQ|About Us

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, IL

Clinical Trial Details

Overview

Research Study Summary

A 17-week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment with LY2140023 Combined with SOC to placebo Combined with SOC as the Treatment of Patients with DSM-IV-TR Schizophrenia with Prominent Negative Symptoms

Purpose

The primary objective of this study is to determine if treatment with LY2140023 compared to placebo (an inactive substance), when added to a fixed dose of a standard of care (SOC) antipsychotic, will demonstrate significantly greater reduction of negative symptoms.

Patients included in this study will be concurrently receiving 1 of 4 current FDA approved antipsychotics: aripiprazole, olanzapine, risperidone, or quetiapine

Please contact Alexian Brothers for more information on participation.

To Learn more
Phase

2

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Duration

17 Weeks

Facility Type

N/A

Contact

Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information: Alexian Brothers Hospital Network

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 176871

Date Last Changed: July 22, 2013


DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.